Researchers uncover the source of cells that contribute to pulmonary fibrosis
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Savara’s Molgramostim: Strong Buy Rating Backed by Clinical and Real-World Evidence for aPAP Treatment
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price ...
Outsourcing-pharma13d
Ethris reports positive phase 1 results for asthma mRNA therapy
Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...
Molgramostim shows promise in rare lung disease treatment
LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a ...
Le Lézard13d
Valley Oaks Health Shares Crisis Response Impact Data and Report to Support Investment in Behavioral Health Crisis Response Systems
Valley Oaks Health, an Indiana Certified Community Mental Health Center serving the behavioral health and primary care needs of nearly 12,000 people each year, and a member of The Indiana ...
Le Lézard13d
Tiger's 1st Pro AV Sale of 2025 Features 700 Plus Lots of High Quality Gear
at 08:40 Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research ...
The EMBO Journal26d
A novel human fetal lung-derived alveolar organoid model reveals mechanisms of surfactant protein C maturation relevant to interstitial lung disease
Alveolar type 2 (AT2) cells maintain lung health by acting as stem cells and producing pulmonary surfactant. AT2 dysfunction underlies many lung diseases, including interstitial lung disease (ILD), in ...
Business Wire1mon
Savara Announces New Employment Inducement Grant
Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Hosted on MSN1mon
Wells Fargo Initiates Coverage of Savara (SVRA) with Overweight Recommendation
Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management ...